Mbs2012408

In the context of this study, we identified tumor-suppressing protein candidates from the TCGA database. Notably, these candidates exhibit significantly elevated transcript levels in patients diagnosed with PDAC when compared to control groups. This heightened expression is associated with a diminished survival rate. Furthermore, these proteins are classified as either secretory proteins or plasma membrane proteins, indicating their presence within the extracellular space. Ten tumor-suppressing protein candidates were employed, including IGHG1, SFN, PSCA, LAMB3, GPRC5A, LZM, KLK10, LUM, APOL1, and CD74 (#MBS2122530, #MBS2009542, #MBS2012408, #MBS2011064, #MBS2123946, #MBS2009419, #MBS2029351, #MBS205400, #MBS2029622, #MBS205925; MyBioSource). In the MTT assay, each of these recombinant proteins (5 μg/mL) was used in the MTT assay. We evaluated the effects of the application of recombinant proteins on the cellular viability (metabolic activities) of Pa03C cells within a two-day timeframe.

Human pancreatic cancer cells such as PANC1 and AsPC-1 (ATCC, Manassas, VA, USA), as well as PANC10.05, PANC198, and Pa03C (obtained from Dr. A. Maitra at MD Anderson Cancer Center, Houston, TX, USA), were cultured in DMEM (Corning, New York, NY, USA). Human mesenchymal stem cells (MSCs) (#PT-2501, Lonza, Basel, Switzerland) were grown in MSCBM (#PT-3238, Lonza). Jurkat T lymphocytes and PC-3 human prostate cancer cells (ATCC) were cultured in RPMI1640. The culture medium was enriched with 10% fetal bovine serum (FBS) and 1% antibiotics, and cells were incubated at 37 °C in a 5% CO₂ atmosphere. Cells were treated with 20 µM CW008 (#5495, Tocris Bioscience, Minneapolis, MN, USA) as an activator of PKA signaling [29 (link)] or 50 µM of Dorsomorphin (#3093, Tocris Bioscience) as an inhibitor of AMPK signaling [30 (link)] for one day. Tumor cells were treated with 2 µg/mL of recombinant PSCA proteins (#MBS2012408; MyBioSource, San Diego, CA, USA), or chemotherapeutic agents, such as Irinotecan (#2688, Tocris Bioscience), 5-Fluorouracil (#3257, Tocris Bioscience), and Oxaliplatin (#2623, Tocris Bioscience).